AIM: To investigate the effects of Glytan on splanchnic hemodynamics and its reduction of portal pressure in portal @entity101 @entity35 . METHODS: Glytan (Ganluotong in Chinese), is composed of @entity26482 and @entity11950 . @entity101 ( @entity101 ) was induced in the @entity35 by common bile duct ligation (BDL). Hemodynamic studies were performed using the colored microsphere method. Radioimmunoassay (RIA) was used to determine @entity1827 levels in the mesenteric circulation. Western blotting methods were used to investigate the effect of Glytan on @entity11081 ( @entity11081 ), @entity10932 ( @entity10932 ), endothelial NO synthase (eNOS), @entity21016 , and b-arrestin 2 expression in the mesentery. The mRNA of @entity11081 and @entity10932 was determined using real-time polymerase chain reaction. RESULTS: Treatment with Glytan reduced portal pressure (PP) and portal territory blood flow (PTBF) and increased both mean arterial pressure (MAP) and splanchnic vascular resistance (SVR). Especially at 4 wk, PP decreased by about 40%, while MAP increased by 13%, SVR increased by 12%, and PTBF decreased by about 21%. The effect of blood flow reduction was greatest in the mesentery (about 33%) at 4 wk. The mesenteric circulation @entity1827 levels of BDL @entity35 were lower and negatively correlated with PP at 4 wk. Glytan can increase mesenteric @entity1827 content and inhibit @entity10932 , eNOS, @entity21016 , and b-arrestin 2 expression in the mesentery. Moreover, Glytan showed no effect on the expression of @entity11081 protein and mRNA. CONCLUSION: The decreased PP and PTBF observed after Glytan treatment were related to increased mesenteric vasoconstriction and increased receptor sensitivity to vasoconstrictor.

Glytan decreases portal pressure via mesentery vasoconstriction in portal XXXX @entity35 .

@entity10932 :: ('50672(Tax:10116)', 'Gene') :: ['ETBR', 'ET B receptor'] @entity101 :: ('MESH:D006973', 'Disease') :: ['PHT', 'Portal hypertension', 'hypertensive'] @entity11950 :: ('MESH:D019695', 'Chemical') :: ['diammonium glycyrrhizinate'] @entity11081 :: ('24326(Tax:10116)', 'Gene') :: ['ETAR', 'ET A receptor'] @entity1827 :: ('24323(Tax:10116)', 'Gene') :: ['ET-1', 'endothelin (ET)-1'] @entity26482 :: ('MESH:C076944', 'Chemical') :: ['salvianolic acid B'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity21016 :: ('25238(Tax:10116)', 'Gene') :: ['GRK2', 'G-protein-coupled receptor kinase (GRK)2']
@entity101 :: (MESH:D006973,Disease) :: ['hypertensive']
